T he members of the TNF superfamily LIGHT 3 (lymphotoxin-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator (HVEM) on T cells) and lymphotoxin ␣1␤2 (LT␣1␤2) bind to the members of the TNF receptor superfamily HVEM and/or LT␤R. Both ligand-receptor pairs play essential roles in the communication between lymphocytes and stromal cells and form a signaling network that has been shown to be necessary for innate and adaptive immune responses. The LIGHT/LT system plays a role in the development of normal lymphoid tissue microenvironments (1, 2) and of organized lymphoid structures in chronically inflamed tissues (3) . LIGHT, which can bind both LT␤R and HVEM, has a costimulatory function for T cell activation. Transgenic LIGHT overexpression leads to chronic T cell activation and autoimmune-like disease (4 -8) , indicating its potential role in autoimmune diseases. Accordingly, disruption of LT/LIGHT signaling alleviates inflammation in many investigated autoimmune disease models. The administration of the decoy receptor LT␤R-Ig fusion protein (LT␤R-Ig) or its transgenic expression blocked disease development in several T cell-mediated models such as diabetes in the autoimmune NOD mouse, experimental colitis, acute rat experimental autoimmune encephalitis, and graft-vs-host disease (9) . Interference with T cell autoreactivity could explain these effects, since genetic deletion of the LIGHT gene decreased CD8 responses under some circumstances (10) . However, the precise role of LIGHT and LT in T cell-activation and differentiation has not been fully clarified.
The LT/LIGHT system is further complicated by the identification of two more receptors of HVEM. The first one identified, B and T lymphocyte attenuator (BTLA/CD272), is a member of coinhibitory receptors belonging to the CD28 Ig superfamily (11, 12) . The most recently identified, CD160, is expressed by T cells and mainly NK cells (13) . Functional data for the interaction of HVEM with both receptors suggest an inhibitory function on CD4 T cell activation (13) . Accordingly, and extending the previously anticipated function of HVEM as a costimulator triggered by LT␣ and LIGHT, results from HVEM knock-out mice as well as from in vitro studies of BTLA-HVEM and CD160-HVEM interaction rather argue for HVEM being a coinhibitory ligand (14) .
Studies investigating the function of the LT/LIGHT pathway in collagen-induced arthritis (CIA) have produced conflicting results. A first study by Fava et al. described LT␤R-Ig fusion protein as an effective inhibitor of CIA development, arresting even established disease (15) . In contrast, two recent publications showed that blockade of LT signaling leads to more severe and prolonged autoimmune arthritis. A study by Han et al. described that in the naturally resistant C57BL/6 strain, deletion of the LT␣ gene led to the development of arthritis following collagen immunization. Additionally, treatment with LT␤R-Ig fusion protein exacerbated CIA in DBA/1J mice (16) . In the absence of LT signaling, enhanced production of Th1 cytokines can be observed, indicating a possible role of those response genes in the mechanisms leading to the exacerbated arthritogenic response. However, data by Chin et al. challenge this explanation. This group was able to confirm that LT␤R Ϫ/Ϫ mice and Lt␣ Ϫ/Ϫ mice are more susceptible to CIA, but the results suggested that a central break of tolerance contributes to the autoimmune arthritis observed. Ectopic thymic expression of type II collagen in medullary thymic epithelial cells contributes to central tolerance, and this expression was found to be dependent on LT␣ (17) . Among the possible explanations, including the opposing roles of the LT pathway in central tolerance vs peripheral inflammation and the utilization of different murine strains or dosages in the studies, LT␤R-Ig mediated blocking of the costimulatory function of LIGHT to HVEM, supposed to decrease T cell activation in CIA, might have contributed to the discrepant results.
To further elucidate the contribution of the LIGHT/HVEM/ BTLA system in CIA, a HVEM-Ig fusion protein blocking LIGHT and LT␣ but not LT␣1␤2 was analyzed. We report herein that blocking LIGHT/LT␣ significantly aggravates both the development and the progression of CIA. The results highlight the complex regulatory role of the LIGHT/LT/BTLA/HVEM system on CD4 T cell responses in autoimmune arthritis.
Materials and Methods

Induction of arthritis and scoring
DBA/1J mice (Harlan Winkelmann) at 7-8 wk of age were immunized with 50 l of a 1:1 (v/v) emulsion of CFA and 0.1 M acetic acid containing 50 g of chick type II collagen (CII; Chondrex) and 50 g of heat-killed M. tuberculosis (Chondrex) at the base of the tail. Development of arthritis was assessed three times weekly by two blinded observers. The clinical severity of arthritis in each paw was quantified according to a graded scale from 0 to 4, as follows: 0, no swelling; 1, swelling in one digit or mild edema; 2, moderate swelling affecting several digits; 3, severe swelling affecting most digits; and 4, the most severe swelling and/or ankylosis. A total arthritis score per mouse was determined by summarizing the scores of all four extremities. The mean Ϯ SEM values were determined.
The injections of the fusion protein and control IgG were i.p. 150 g per mouse. All of these experiments were performed in a strict specific pathogen-free facility at the University of Leipzig. All experimental procedures were performed according to the German animal care and ethics legislation and had been approved by the local government authorities.
Fusion protein
The murine HVEM-human IgG1 Fc and murine LT␤R-human IgG1 Fc fusion proteins were produced as described previously (18) . The recombinant baculoviruses encoding the fusion proteins were purchased from Orbigen. In brief, the fusion proteins were produced from insect cells, purified by conventional protein A-based affinity chromatography, and tested to contain Ͻ0.5 endotoxin units per milligram of protein using the Limulus amebocyte lysate assay (BioWhittaker). Quantification of protein was performed using the Bradford assay and verified by SDS-PAGE. Both constructs were found to bind human and murine LIGHT expressed on the cell surface in a comparable manner in FACS-binding experiments. Additionally, HVEM-Ig was shown to bind mouse BTLA (see supplemental Fig.  1 ). 4 Clinical grade polyclonal human IgG was used as control protein. For in vitro T cell proliferation experiments, HVEM cleaved from the Fc part was produced by digestion with pepsin (Pierce Biotechnology).
T cell proliferation assays and cytokine production
Draining lymph nodes were removed under aseptic conditions and singlecell suspensions of mononuclear cells of pooled lymph nodes from individual mice were prepared. The cells were washed three times in culture medium before being suspended to 2 ϫ 10 6 mononuclear cells per milliliter in round-bottom 96-well polystyrene microtiter plates (Nunc) in a total volume of 200 l. The culture medium consisted of RPMI 1640 with Glutamax II (Invitrogen) supplemented with 50 IU/ml penicillin, 60 g/ml streptomycin, and 5% inactivated FBS (all from Invitrogen). For lymphocyte stimulation, denatured pepsin-free T cell proliferation grade CII (Chondrex) was added to cultures at final concentrations of 10 and 50 g/ml. Cells were incubated at 37°C in humidified air with 5% CO 2 . After 3 days cells were pulsed with 10 l of [ 3 H]methylthymidine (1 Ci/well; Amersham Pharmacia Biotech) and cultured for an additional 24 h. Cells were harvested onto glass-fiber filters (PerkinElmer) and [ 3 H]thymidine incorporation was measured in a liquid beta scintillation counter. The results were expressed as cpm. For proliferation assays, cultures were done in triplicates. Additionally, supernatants were collected from the cell cultures and frozen at Ϫ80°C, and concentrations of IFN-␥ in the supernatants were determined by the Cytoscreen immunoassay kit (BioSource International).
FACS analysis of B and T cell populations was conducted by surface staining for CD19 (7G8), CD62L, CD86, CD44, CD4, and CD25 (BD Biosciences) and for intracellular Foxp3 (eBioscience) according to published protocols.
Measurement of collagen-specific Abs and cytokines
Sera were collected at day 30 by retroorbital blood drawing and at the day of sacrifice (day 45 after immunization) from heart blood drawings. After the samples had fully coagulated, they were centrifuged and the sera were stored at Ϫ80°C. Levels of CII-specific IgG2a and IgG1 were determined by ELISA using CII-coated ELISA plates for capture and goat anti-mouse IgG2a and IgG1 Abs for detection. Absorbance (450 nm) was measured with an ELISA plate reader (Wallac). The measurements were done in triplicate.
Serum cytokine concentrations for IL-6, IL-12, TNF-␣, IFN-␥, and MCP-1 were analyzed by cytometric bead array (CBA mouse inflammation kit; BD Biosciences) according to the manufacturer's protocol.
Histopathologic assessment
Mouse paws were fixed in 4% neutral buffered formalin (Sigma-Aldrich) and then decalcified, cut, and stained with H&E. The sections were scored by two independent observers, at low power for cellular infiltration, exudation, and pannus, and at low (ϫ10) and high (ϫ100 or ϫ200) power for bone erosion and cartilage destruction.
A semiquantitative graded scale from 0 to 3 was used, as follows: 0, no changes; 1, mild changes; 2, moderate changes; and 3, most severe changes observed in the experiments. A mean score for each animal was determined for each parameter, and these scores were averaged to determine group means.
Radiographic examination
Lateral contact radiographs of both knee joints were obtained using a Siemens x-ray cabinet and high-resolution mammography film (Eastman Kodak). Destruction of bone and cartilage was classified, without knowledge of the assigned treatment groups, by judgment of proliferative and erosive changes, joint space narrowing, and the presence of ankylosis, according to a graded scale from 0 to 3, as follows: 0, no changes; 1, mild changes; 2, moderate changes; 3, most severe changes observed in the experiments.
Statistical analysis
Statistical differences were analyzed using the Mann-Whitney U test or the two-tailed Student's t test where appropriate.
Results
Treatment with soluble HVEM-Ig fusion protein exacerbates CIA
To study the effect of treatment with HVEM-Ig on the development of autoimmune arthritis, DBA/1J mice were immunized with 4 The online version of this article contains supplemental material. Mice were injected i.p. either HVEM-Ig fusion protein (‚, n ϭ 18), LT␤R-Ig fusion protein (Ⅺ, n ϭ 12) or IgG control protein (E, n ϭ 24). Arthritis was evaluated using a semiquantitative scoring system (see Materials and Methods for details). HVEM-Ig-treated mice had significantly higher arthritis scores than did LT␤R-Ig-or control Ig-treated mice (mean Ϯ SEM; ‫,ء‬ p Ͻ 0.05).
bovine CII in CFA. After the induction of arthritis, mice were injected i.p. with either soluble HVEM-Ig fusion protein or control human Ig. In a first group of animals, treatment was initiated immediately after immunization to investigate the effect of HVEM-Ig administered during the preclinical phase. In a second group, animals were treated in the late, chronic phase of CIA with apparent disease and dominating inflammatory mechanisms. To further clarify the role of the LIGHT/LT system, a LT␤R-Ig fusion protein was used in a set of experiments analogous to the HVEM-Ig protein.
When mice were treated with HVEM-Ig during the preclinical phase twice weekly, the ensuing arthritis during follow-up was more severe than in the control mice and more severe than in the LT␤R-Ig fusion protein-treated mice, while no difference between the latter and the control group was discernable (Fig.  1) . Additionally, a tendency toward an earlier onset of disease was observed in the HVEM-Ig-treated mice in this treatment group, and the weight loss following the immunization with CII was higher (data not shown).
In the second treatment group, HVEM-Ig, LT␤R-Ig, or control Ig were administered only after the clinical onset of arthritis (beginning between day 25 and 31 postimmunization) twice weekly for up to 3 wk. In contrast to the group treated in the preclinical phase, no influence of the fusion proteins on the course of established arthritis was observed (data not shown).
Erosive joint destruction is enhanced in HVEM-Ig-treated mice
To investigate joint histopathology, paws were dissected from HVEM-Ig and control human Ig-treated mice, stained with H&E, and evaluated in blinded fashion for signs of arthritis.
In agreement with the clinical results, the histological analysis also showed more severe arthritis in the group treated with HVEM-Ig in the preclinical phase compared with the control-Igand LT␤R-Ig-treated groups (data not shown). The animals had significantly higher numbers of proliferating synoviocytes and of infiltrating inflammatory cells in their affected joints. Pannus development was more pronounced, and erosions of bone and cartilage were increased compared with controls ( Fig. 2A-C) .
In addition to the histological analysis, radiographs of both hind knee joints were taken and analyzed by two trained blinded investigators. Again, a significant aggravation of joint and bone destruction was observed in the paws of HVEM-Ig-treated mice compared with the controls (Fig. 2, D and E) . The most pronounced differences were found in proliferative changes and in the development of joint ankylosis, but joint erosion and joint space narrowing were also significantly increased in the HVEM-Ig-treated mice (Fig. 2F) .
Effect of HVEM-Ig treatment on the Ab response to collagen
To investigate the influence of HVEM-Ig treatment on the humoral immune response to collagen, sera obtained from mice at day 30 and day 45 after immunization were analyzed for CII-specific IgG Abs by quantitative ELISA. At day 30 after immunization, mice treated with HVEM-Ig in the preclinical phase of the disease had significantly higher concentrations of IgG2a anti-CII Abs compared with the controls (mean concentration, 4.6 (Ϯ0.4) ϫ 10 5 vs 2.8 (Ϯ0.3) ϫ 10 5 U, p Ͻ 0.05; Fig. 3 ). However, the observed difference in IgG2a anti-CII Ab concentration was not discernible anymore at the later time point of observation 45 days after immunization, and the determined levels of IgG1 anti-CII Abs did also not differ between treated animals and controls.
HVEM-Ig-treated mice mount an enhanced T cell response toward CII
To analyze the influence of HVEM-Ig treatment on T cell responses in CIA, recall responses to CII were examined. For that purpose, cells isolated from spleens and draining lymph nodes of CII-immunized mice treated with either HVEM-Ig or control Ig were isolated and restimulated in vitro. HVEM-Ig treatment in the preclinical phase enhanced the recall response of CD4 ϩ T cells to CII in all experiments significantly (Fig. 4) .
Additionally, to analyze the effect of HVEM-Ig treatment on the phenotype of CD4 ϩ T cell in vivo, peripheral blood CD4 ϩ T cells collected at day 30 after immunization were investigated by flow cytometry. Mice treated with HVEM-Ig were found to have a higher percentage of CD25 ϩ CD4 T cells compared with controls, while CD62L expression on CD4 T cells was diminished significantly (Fig. 5) . No difference was seen in the frequency of CD25 ϩ
Foxp3
ϩ , regulatory CD4 ϩ T cells (data not shown), however, indicating that the increase in CD25 ϩ CD4 ϩ T cells was due to an increase in activated rather than to regulatory T cells.
In accordance with the presence of high numbers of activated T cells, increased concentrations of the T cell cytokine IFN-␥ were present in sera of HVEM-Ig-treated mice at day 30 after immunization. Additionally, the monocytic cytokine IL-6 was also found in increased concentration in HVEM-Ig-treated animals compared with controls (Fig. 6) .
HVEM-Ig increases Ag-dependent in vitro recall proliferation of T cells
To analyze the direct effect of the HVEM-Ig fusion protein on Ag-dependent T cell proliferation in vitro, spleen and lymph node cells were isolated from untreated mice with CIA and used in an in vitro assay. To rule out that FcR binding influences the assay, HVEM-Ig was digested with pepsin. The isolated spleen and lymph node cells were used in an in vitro proliferation assay, and cell divisions were measured by [ 3 H]thymidine incorporation and IFN-␥ secretion was determined with and without addition of CII to the cultures.
In the presence of both complete HVEM-Ig and of HVEM without the Ig Fc domain, collagen II-dependent and -independent in vitro proliferation as well as IFN-␥ secretion were significantly up-regulated compared with the control assays (Fig. 7) .
Discussion
Results from previous studies suggested that LIGHT has a costimulatory activity that is mediated by engagement with HVEM (19) . Interference with the action of LIGHT in CIA by using LT␤R-Ig fusion protein has produced conflicting results, and more specific targeting of LIGHT has not been analyzed in this model so far. To further elucidate the contribution of the LIGHT/HVEM axis in CIA, a HVEM-Ig fusion protein, which has been shown to block the effects of LIGHT but not of LT␣1␤2 (18), was analyzed. When HVEM-Ig was administered during the establishment of the autoimmune response, but before the clinical onset of disease, an aggravated development of arthritis was observed. The increase in clinical and histopathological severity of arthritis following HVEM-Ig treatment was accompanied by an augmented CII-specific T cell response and by a higher frequency of activated splenic T cells, which argues for a direct influence of LIGHT on T cell priming and activation threshold. The direct effect of HVEM-Ig on T cell activation could be mimicked in in vitro assays with splenic and lymph node cells from previously untreated mice. In those assays, the proliferative reponses elicited by CII as recall Ag were significantly increased by HVEM protein, and this effect was independent of the attached Ig-Fc domain.
In contrast, LT␤R-Ig injected after the immunization did not influence the course of CIA, the production of IFN-␥, or the proliferation of T cells (data not shown). Since LT␤R-Ig can block LIGHT but not BTLA, CD160, or LT␣ (see Fig. 8A ), the disease aggravation observed for HVEM-Ig treatment is likely mediated by interference with one of these ligands, while LIGHT may not play a significant role in this model (see Fig. 8B ). However, the interaction of HVEM-Ig with membrane-anchored or soluble LIGHT might elicit other effects than the interaction with LT␤R-Ig. Since LIGHT itself is a costimulatory receptor expressed on T cells that transmits reverse signals after ligation with HVEM (20, 21) , the HVEM-Ig fusion protein could specifically costimulate T cells in CIA (Fig. 8B, ᮍ b ). Similar effects have been shown for several other TNF family ligands and TNFR family members; for example, for TNFR1 after ligation of membrane TNF (22) , and for CD30 following interaction with CD30L (23).
However, since our HVEM-Ig fusion protein binds mouse BTLA, and since an aggravation of arthritis was observed only with HVEM-Ig treatment, but not with LT␤R-Ig, the other scenarios involving BTLA or CD160 (Fig. 8B, ᮍ a ) are more likely. In the first scenario, functional interference with the recently characterized HVEM-BTLA interaction (11, 12, 14) by HVEM-Ig may explain its effect. Engagement of BTLA on T cells with surface-expressed HVEM delivers an inhibitory signal by inducing the tyrosine phosphorylation of BTLA, thereby leading to an association of HVEM with SHP-2 (Src homology domain 2-containing phosphatase), which is similar to the inhibitory receptors CTLA-4 and PD-1 (programmed death-1) (24, 25) . This regulatory network is increasingly complex because HVEM has the potential to bind BTLA and LIGHT simultaneously (11, 26, 27) . However, like anti-BTLA Abs that have been developed as either BTLAblocking or -stimulating substances (12, 28) , the fusion protein used may have an inhibitory activity in the investigated mouse strain. On the other hand, BTLA itself may sustain the autoimmune anti-CII T cell response, a role that derives from the recent observation of a role for BTLA in sustaining CD4 ϩ T cell survival under the conditions of chronic stimulation in the nonirradiated parental-into-F 1 graft-vs-host disease model (29) . Therefore, a BTLA-HVEM-Ig interaction may have contributed to the aggravated disease either by blocking the BTLA-mediated inhibitory signal (see ᮍ a in Fig. 8B ) or by inducing a survival signal following ligation of T cell-expressed BTLA. Of note, a recent study has identified CD160 as another binding partner of HVEM with suppressive activity on CD4 T cells. Functional consequences of CD160-HVEM ligation for the outcome of CD4 T cell stimulation appear to be inhibition of T cell activation, much like the effect of BTLA-HVEM interaction. However, in a recently published study, strong T cell activation by anti-CD3 and anti-CD28 Abs was not inhibited by anti-CD160, anti-BTLA Abs, or HVEM-Ig, while CD4 T cell memory responses or alloresponses that depend on direct APC-T cell interaction were even enhanced by anti-CD160, anti-BTLA, or anti-HVEM Abs (13) . Hence, a mechanism involving simultaneous ligation of CD160 together with BTLA (see ᮍ a in Fig. 8B ) seems to be a likely explanation for the aggravation of CIA in our experiments. Further studies investigating such possibilities are required.
A second scenario is based on the binding properties that differentiate HVEM-Ig from LT␤R-Ig. HVEM-Ig, but not LT␤R-Ig, can bind trimeric LT␣ (30) , and abrogation of LT␣-derived effects may contribute to disease aggravation (see Fig. 8A ). This concept of arthritis-inhibiting effects of LT␣ is supported by a recent report describing exacerbated CIA in Lt␣ Ϫ/Ϫ mice (16) . In addition to knocking out LT␣, this group also used LT␤R-Ig as a blocking agent, since LT␣-deficient mice have severely compromised secondary lymphoid organs. The group found significantly up-regulated arthritis in LT␤R-Ig-treated mice, which contrasts with our results and another report describing disease suppression with LT␤R-Ig treatment (15) .
CIA is critically dependent on the function of B cells, which is illustrated by the fact that under certain conditions, the disease can be elicited simply by transfer of anti-CII Abs. The T cell-dependent differentiation of B lymphocytes is tightly regulated by interactions between members of the TNF ligand and receptor families, such as CD40/CD40L, CD27/CD70, and CD134/CD314L. HVEM expression has been shown to occur on memory and naive B cells, and LIGHT enhanced both B cell proliferation and Ig production (31) . Despite this importance of LIGHT for humoral immunity, HVEM-Ig-treated mice developed a stronger Ab response, in particular of Abs of the subclass IgG2a, the most important pathogenic Abs. Additionally, T cell reactivity was increased in the HVEM-Ig-treated animals, most likely due to a stimulatory effect of the HVEM on T cells. It can be hypothesized, therefore, that the enhanced autoantibody response in HVEM-Ig-treated mice is the result of T cell-induced B cell activation, with other TNF family ligand-receptor pairs substituting the LIGHT-HVEM interaction.
LIGHT is up-regulated in the joints of patients with rheumatoid arthritis and mediates proinflammatory effects on joint-resident cells as macrophages (32) and fibroblasts (33) . The rational for blocking LIGHT in mice with established joint inflammation was to investigate a phase of the disease in which adaptive immune responses are of minor importance, and to test whether the disease is still influenced. LIGHT blockade during the chronic stadium of the disease exerted no significant influence on the course of the disease, indicting that LIGHT as a proinflammatory mediator plays a lesser role in murine CIA compared with human rheumatoid arthritis. This notion was supported by low amounts of LIGHT message in synovial tissue from CIA mice (data not shown). However, the lack of efficacy of HVEM-Ig in the late phase of disease might also stem from opposing effects of HVEM-Ig on adaptive immunity. Adaptive immunity might still be contributing to this chronic stadium, and inhibiton of this system might outweigh the effect of direct inhibition of the proinflammatory effects, which LIGHT exerts on human rheumatoid arthritis synoviocytes (33) . Our study expands data from two previous manuscripts published with opposing results (15, 16) , which used LT␤R-Ig in the chronic phase of CIA with no conlusive evidence for a pro-or antiinflammatory role for the investigated molecules LIGHT and LT␣1␤2.
Consequently, further studies directed on the inhibition of proinflammatory signals from BTLA, CD160, HVEM, LT, and LIGHT as treatment strategy for human rheumatoid arthritis are required, but HVEM-Ig fusion protein is not a promising approach.
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